SC-CAR.GPC3xIL15.21 CAR T cells (Seattle Children'S Hospital)

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameSC-CAR.GPC3xIL15.21 CAR T cells (Seattle Children'S Hospital)
Drug Alias NameSC-CAR.GPC3xIL15.21 T cells
ClassificationCell and gene therapy > Cell therapy > Source of cells > PMBC-derivedCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous +[4] 
Mechanisms of ActionAnti-Glypican-3Interleukin-15 modulatorsInterleukin-21 modulators
TargetsGlypican-3Interleukin-15Interleukin-21
Therapy Area/IndicationsSolid tumoursCarcinoma, HepatocellularEndodermal Sinus Tumor +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSeattle Children'S Hospital
China Registration ClassN/A

Develop Information

Active CompaniesSeattle Children'S Hospital
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, HepatocellularEndodermal Sinus Tumor +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A